ACAD vs XENE
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
ACAD · ACADIA Pharmaceuticals$21.23 ▼ 0.05%
XENE · Xenon Pharmaceuticals$39.17 ▲ 3.95%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- ACAD -4.4%
- XENE +2.0%
Head to head
| Metric | ACAD | XENE |
|---|---|---|
| Price | $21.23 | $39.17 |
| Change today | ▼ 0.05% | ▲ 3.95% |
| Market cap | $3.67B | $3.79B |
| Return, 3 months | -27.8% | -39.0% |
| Return, year to date | -20.5% | -12.6% |
| Return, 1 year | -5.9% | +2.4% |
| P/E (TTM) | 10.0 | -8.3 |
| P/B | 2.6 | 3.1 |
| P/E percentile vs own 5y | 58th | 98th |
| Dividend yield | – | – |
| Revenue growth (YoY, latest qtr) | +16.4% | – |
| Net profit growth (YoY) | +18.1% | -30.7% |
| Gross margin | 91.1% | – |
| Operating margin | 7.6% | – |
| Net margin | 33.4% | – |
| Return on equity | 35.7% | -43.6% |
| Analyst target vs. price | +52.3% | +89.7% |
| Analyst buy share | 83% | 100% |
| RSI (14) | 52 | 53 |
| 30-day volatility | 32.3% | 37.9% |
| Max drawdown, 1 year | -39.1% | -52.8% |
| Trend read | Leaning bullish | Leaning bullish |
| Analyst consensus | Buy | Buy |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- XENE is the largest of the group by market value.
- XENE has returned the most over the past year.
- XENE carries the lowest trailing P/E.
- ACAD has been the calmest stock over the last 30 days.